Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis

Overview

Journal Adv Ther

Date 2020 Nov 6

PMID 33155180

Citations 26

Authors

Le Wang

Xiaozhong Guo

Xiangbo Xu

Valerio De Stefano

Aurelie Plessier

Carlos Noronha Ferreira

Xingshun Qi

Affiliations

Soon will be listed here.

Abstract

Introduction: Benefit and risk of anticoagulation in cirrhotic patients with portal vein thrombosis (PVT) remain controversial, especially in those with asymptomatic PVT and in non-liver transplant candidates. Furthermore, the predictors of portal vein recanalization and bleeding events after anticoagulation are critical for making clinical decisions, but still unclear. We conducted a meta-analysis to investigate the outcomes of anticoagulation for PVT in liver cirrhosis and explore the predictors of portal vein recanalization and bleeding events after anticoagulation.

Methods: All studies regarding anticoagulation for PVT in liver cirrhosis were searched via PubMed, EMBASE, and Cochrane Library databases. Thrombotic outcomes, bleeding events, and survival were compared between anticoagulation and non-anticoagulation groups. Predictors of portal vein recanalization and bleeding events were pooled. Risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs) were calculated.

Results: Thirty-three studies including 1696 cirrhotic patients with PVT were included. Anticoagulation significantly increased portal vein recanalization (RR = 2.61; 95% CI 1.99-3.43; P < 0.00001) and overall survival (RR = 1.11; 95% CI 1.03-1.21; P = 0.01) and decreased thrombus progression (RR = 0.26; 95% CI 0.14-0.49; P < 0.0001). Anticoagulation did not significantly influence overall bleeding (RR = 0.78; 95% CI 0.47-1.30; P = 0.34). Early initiation of anticoagulation (RR = 1.58; 95% CI 1.21-2.07; P = 0.0007) significantly increased portal vein recanalization. Child-Pugh class B and C (RR = 0.77; 95% CI 0.62-0.95; P = 0.02) and higher MELD score (MD = - 1.48; 95% CI - 2.20-0.76; P < 0.0001) were significantly associated with decreased portal vein recanalization. No predictor significantly associated with bleeding events was identified.

Conclusions: Early initiation of anticoagulation should be supported in liver cirrhosis with PVT. Predictors of portal vein recanalization should be taken into consideration to identify those who may not benefit from anticoagulation.

Registration: The work was registered in PROSPERO with registration no. CRD42020157142.

Citing Articles

Administration of anticoagulation strategies for portal vein thrombosis in cirrhosis: network meta-analysis.

Li H, Yin F, Ma Y, Gao T, Tao Y, Liu X Front Pharmacol. 2025; 15():1462338.

PMID: 39834816 PMC: 11743941. DOI: 10.3389/fphar.2024.1462338.

Thrombotic, Cardiovascular, and Microvascular Complications of Myeloproliferative Neoplasms and Clonal Hematopoiesis (CHIP): A Narrative Review.

Schafer A, Mann D J Clin Med. 2024; 13(20).

PMID: 39458034 PMC: 11508398. DOI: 10.3390/jcm13206084.

Analysis of factors related to recanalization of portal vein thrombosis in liver cirrhosis: a retrospective cohort study.

Shi Y, Feng W, Cai J, Wang Z, Pu Y, Mao W BMC Gastroenterol. 2024; 24(1):224.

PMID: 39003447 PMC: 11245851. DOI: 10.1186/s12876-024-03322-8.

Systemic Thrombolysis for Isolated Splenic Vein Thrombosis Secondary to Oral Contraceptives: A Case Report.

Li Q, Wang R, Qi X Int J Womens Health. 2024; 16:811-818.

PMID: 38765206 PMC: 11100964. DOI: 10.2147/IJWH.S462610.

Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis.

Tadokoro T, Tani J, Manabe T, Takuma K, Nakahara M, Oura K Sci Rep. 2024; 14(1):10784.

PMID: 38734732 PMC: 11088711. DOI: 10.1038/s41598-024-60235-y.

References

Intagliata N, Caldwell S, Tripodi A . Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology. 2019; 156(6):1582-1599.e1. DOI: 10.1053/j.gastro.2019.01.265. View

Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou P . Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2014; 61(2):660-7. DOI: 10.1002/hep.27546. View

Stine J, Shah P, Cornella S, Rudnick S, Ghabril M, Stukenborg G . Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis. World J Hepatol. 2015; 7(27):2774-80. PMC: 4663397. DOI: 10.4254/wjh.v7.i27.2774. View

Simonetto D, Singal A, Garcia-Tsao G, Caldwell S, Ahn J, Kamath P . ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. Am J Gastroenterol. 2020; 115(1):18-40. DOI: 10.14309/ajg.0000000000000486. View

De Franchis R . Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015; 63(3):743-52. DOI: 10.1016/j.jhep.2015.05.022. View

Qi X, Guo X, Yoshida E, Mendez-Sanchez N, De Stefano V, Tacke F . Transient portal vein thrombosis in liver cirrhosis. BMC Med. 2018; 16(1):83. PMC: 5989335. DOI: 10.1186/s12916-018-1069-8. View

Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D . Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015; 26(1):23-9. DOI: 10.1016/j.ejim.2014.12.002. View

Chen H, Liu L, Qi X, He C, Wu F, Fan D . Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2015; 28(1):82-9. DOI: 10.1097/MEG.0000000000000482. View

Hanafy A, Abd-Elsalam S, Dawoud M . Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol. 2018; 113:86-91. DOI: 10.1016/j.vph.2018.05.002. View

10.

Hidaka H, Kokubu S, Sato T, Katsushima S, Izumi N, Igura T . Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, double-blind, controlled trial. Hepatol Res. 2017; 48(3):E107-E116. DOI: 10.1111/hepr.12934. View

11.

Cai M, Zhu K, Huang W, Meng X, He K, Zhou B . Portal vein thrombosis after partial splenic embolization in liver cirrhosis: efficacy of anticoagulation and long-term follow-up. J Vasc Interv Radiol. 2013; 24(12):1808-16. DOI: 10.1016/j.jvir.2013.08.018. View

12.

Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Shinohara F, Nakamura Y . Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2017; 48(1):51-58. DOI: 10.1111/hepr.12895. View

13.

Scheiner B, Stammet P, Pokorny S, Bucsics T, Schwabl P, Brichta A . Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. Wien Klin Wochenschr. 2018; 130(13-14):446-455. PMC: 6061656. DOI: 10.1007/s00508-018-1351-y. View

14.

Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B . Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005; 54(5):691-7. PMC: 1774501. DOI: 10.1136/gut.2004.042796. View

15.

Amitrano L, Guardascione M, Menchise A, Martino R, Scaglione M, Giovine S . Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2009; 44(6):448-51. DOI: 10.1097/MCG.0b013e3181b3ab44. View

16.

Delgado M, Seijo S, Yepes I, Achecar L, Catalina M, Garcia-Criado A . Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012; 10(7):776-83. DOI: 10.1016/j.cgh.2012.01.012. View

17.

Senzolo M, M Sartori T, Rossetto V, Burra P, Cillo U, Boccagni P . Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int. 2012; 32(6):919-27. DOI: 10.1111/j.1478-3231.2012.02785.x. View

18.

Werner K, Sando S, Carey E, Vargas H, Byrne T, Douglas D . Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci. 2013; 58(6):1776-80. DOI: 10.1007/s10620-012-2548-y. View

19.

Chung J, Kim G, Lee J, Ok K, Jang E, Jeong S . Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis. Clin Mol Hepatol. 2014; 20(4):384-91. PMC: 4278070. DOI: 10.3350/cmh.2014.20.4.384. View

20.

Cui S, Shu R, Yan S, Wu H, Chen Y, Wang L . Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol. 2015; 27(8):914-9. DOI: 10.1097/MEG.0000000000000351. View